2016
Alcohol Misuse and Co‐Occurring Mental Disorders Among New Soldiers in the U.S. Army
Stein MB, Campbell‐Sills L, Gelernter J, He F, Heeringa SG, Nock MK, Sampson NA, Sun X, Jain S, Kessler RC, Ursano RJ, Collaborators S. Alcohol Misuse and Co‐Occurring Mental Disorders Among New Soldiers in the U.S. Army. Alcohol Clinical And Experimental Research 2016, 41: 139-148. PMID: 27883222, PMCID: PMC5205544, DOI: 10.1111/acer.13269.Peer-Reviewed Original ResearchConceptsAlcohol use disorderBinge drinkingAlcohol misuseMental disordersHeavy drinkingAdverse outcomesAssociation of AUDSuicidal ideationProbable alcohol use disorderOnset of AUDSubstance abuse/dependencePrior alcohol use disordersPrior mental disordersLifetime alcohol use disorderStrong bidirectional associationLifetime alcohol consumptionAbuse/dependenceCohort of soldiersBasic combat trainingDiscrete-time survival analysisOverall burdenUse disordersAlcohol consumptionDrug useSurvival analysis
2015
Polygenic risk for alcohol dependence associates with alcohol consumption, cognitive function and social deprivation in a population‐based cohort
Clarke T, Smith AH, Gelernter J, Kranzler HR, Farrer LA, Hall LS, Fernandez‐Pujals A, MacIntyre DJ, Smith BH, Hocking LJ, Padmanabhan S, Hayward C, Thomson PA, Porteous DJ, Deary IJ, McIntosh AM. Polygenic risk for alcohol dependence associates with alcohol consumption, cognitive function and social deprivation in a population‐based cohort. Addiction Biology 2015, 21: 469-480. PMID: 25865819, PMCID: PMC4600406, DOI: 10.1111/adb.12245.Peer-Reviewed Original ResearchConceptsCognitive abilitiesCognitive functionAlcohol dependenceCognitive impairmentPrevalence of problemsPolygenic risk scoresOnset of dependenceCognitive dysfunctionFamily Health StudyScottish Family Health StudySocial deprivationSignificant negative associationHeavy drinkingGenetic overlapNegative associationImpairmentPhenotypic associationsAlcohol consumptionCognitionDeprivationFuture workPresent studyAbilityAssociationDrinking
2014
Posttreatment Effects of Topiramate Treatment for Heavy Drinking
Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. Posttreatment Effects of Topiramate Treatment for Heavy Drinking. Alcohol Clinical And Experimental Research 2014, 38: 3017-3023. PMID: 25581656, PMCID: PMC4293099, DOI: 10.1111/acer.12578.Peer-Reviewed Original ResearchConceptsPercent days abstinentHeavy drinking daysTopiramate treatmentHeavy drinkingDrinking daysHeavy drinkersAllele homozygotesPlacebo-controlled trialEffects of topiramateEnd of treatmentPersistent therapeutic effectKainate receptor subunitsHigher percent days abstinentTherapeutic effectTreatment goalsAlcohol-related problemsAllele carriersDays abstinentAbstinent daysPosttreatment effectsReceptor subunitsReduced drinkingSingle nucleotide polymorphismsStatistical significanceComplete dataPharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias AJ, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal On Addictions 2014, 23: 288-293. PMID: 24724887, PMCID: PMC4600600, DOI: 10.1111/j.1521-0391.2014.12102.x.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DeterrentsAlcoholismDiagnosis, Dual (Psychiatry)DisulfiramDopamine beta-HydroxylaseDrug Therapy, CombinationFemaleGenotypeHeterozygoteHumansMaleMental DisordersMiddle AgedNaltrexoneNarcotic AntagonistsPolymorphism, Single NucleotideReceptors, Opioid, muTreatment OutcomeVeteransWhite PeopleConceptsAllele carriersHeavy drinkingCo-occurring alcohol dependenceT allele carriersAlcohol-dependent subjectsAD treatment responseTreatment of individualsPrimary outcomePharmacogenetic interactionsHigher overall rateTreatment responseAxis INaltrexoneT carriersEuropean-American subjectsOPRM1 rs1799971Favorable responseMore abstinenceAlcohol dependenceDependent subjectsDBH rs1611115DisulfiramGenotyped subjectsAbstinenceLess drinkingTopiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism
Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism. American Journal Of Psychiatry 2014, 171: 445-452. PMID: 24525690, PMCID: PMC3997125, DOI: 10.1176/appi.ajp.2013.13081014.Peer-Reviewed Original ResearchConceptsHeavy drinking daysHeavy drinkersTopiramate treatmentDaily doseHeavy drinkingTopiramate's effectsDrinking daysAbstinent daysUse of topiramateMaximal daily doseWeeks of treatmentC allele homozygotesPersonalized treatment optionsEnzyme γ-glutamyl transpeptidasePlacebo groupΓ-glutamyl transpeptidaseTreatment optionsTreatment completionPharmacogenetic findingsTreatment goalsAlcohol-related problemsKainate receptorsTreatment groupsBrief counselingAlcohol dependence
2013
Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias A, Gelernter J, Gueorguieva R, Ralevski E, Petrakis I. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal On Addictions 2013 DOI: 10.1111/j.1521-0391.2013.12102.x.Peer-Reviewed Original ResearchAllele carriersHeavy drinkingCo-occurring alcohol dependenceT allele carriersAlcohol-dependent subjectsAD treatment responseTreatment of individualsPrimary outcomePharmacogenetic interactionsHigher overall rateTreatment responseAxis INaltrexoneT carriersEuropean-American subjectsFavorable responseOPRM1 rs1799971More abstinenceAlcohol dependenceDependent subjectsDBH rs1611115DisulfiramGenotyped subjectsAbstinenceLess drinking
2008
Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers
Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Mäkelä R, Kranzler HR. Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers. Alcohol Clinical And Experimental Research 2008, 32: 1159-1166. PMID: 18537939, PMCID: PMC2950972, DOI: 10.1111/j.1530-0277.2008.00735.x.Peer-Reviewed Original ResearchConceptsOpioid receptor geneSingle nucleotide polymorphismsTherapeutic effectReceptor geneHeavy drinkingOpioid antagonist nalmefenePlacebo-controlled trialKappa-opioid receptorsNaltrexone treatment responseHeavy drinking daysReceptor gene polymorphismsOpioid receptor gene polymorphismsAsn40Asp polymorphismNalmefene treatmentPolymorphic variationAntagonist treatmentMedication responseTreatment responsePharmacogenetic analysisReceptor gene variationDrinking daysNalmefeneGene polymorphismsHeavy drinkersConflicting results
2007
Variation in GABRA2 Predicts Drinking Behavior in Project MATCH Subjects
Bauer LO, Covault J, Harel O, Das S, Gelernter J, Anton R, Kranzler HR. Variation in GABRA2 Predicts Drinking Behavior in Project MATCH Subjects. Alcohol Clinical And Experimental Research 2007, 31: 1780-1787. PMID: 17949392, PMCID: PMC3169387, DOI: 10.1111/j.1530-0277.2007.00517.x.Peer-Reviewed Original ResearchConceptsTwelve-step facilitationMotivational enhancement therapyCognitive behavioral therapyPsychosocial treatmentsSingle nucleotide polymorphismsAlcohol dependenceGABRA2 single nucleotide polymorphismsMulti-center randomized clinical trialHeavy drinkingRandomized clinical trialsLow-risk allelesPost-treatment periodPresent studyClinical trialsLower riskEuropean-American subjectsAlcoholism treatmentBehavioral therapyGABRA2 genotypeGABRA2 geneEnhancement therapyLower daily probabilityDrinking outcomesGenetic vulnerabilityPrevious studiesOpioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study
Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, Group T. Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. Alcohol Clinical And Experimental Research 2007, 31: 555-563. PMID: 17374034, DOI: 10.1111/j.1530-0277.2007.00339.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismConfidence IntervalsDNADouble-Blind MethodExonsFemaleGenetic VariationGenotypeHumansLinear ModelsLogistic ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOdds RatioProportional Hazards ModelsPsychiatric Status Rating ScalesReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, muSmokingTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAlcohol dependenceOpioid receptorsTreatment responseVA Cooperative StudyRate of relapsePredictors of responseAlcohol-dependent male subjectsMu-opioid receptorsKappa-opioid receptorsCourse of treatmentShort-term treatmentReceptor gene variantsOpioid receptor geneAsn40Asp polymorphismAvailable medicationsNaltrexone treatmentSpecific pharmacotherapyPretreatment numberDrug naltrexoneNaltrexoneMale subjectsCooperative StudyRelapseHeavy drinkingIndividual single nucleotide polymorphisms
2003
A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP. A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients. Neuropsychopharmacology 2003, 28: 1546-1552. PMID: 12813472, DOI: 10.1038/sj.npp.1300219.Peer-Reviewed Original ResearchConceptsΜ-opioid receptorAlcohol-dependent patientsAbstinence ratesPlacebo-controlled clinical trialOverall abstinence ratesΜ-receptor antagonistWeeks of treatmentΜ-opioid receptor geneAlcohol-dependent individualsAsn40 alleleAsp40 alleleProperties of alcoholRelapse rateNaltrexone responseOpioid systemClinical trialsTreatment outcomesNaltrexoneFunctional polymorphismsGenotype groupsPatientsHeavy drinkingDrinking outcomesReceptor geneSpecific polymorphisms